Samil Pharmaceutical Co Ltd
KRX:000520
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Samil Pharmaceutical Co Ltd
Operating Income
Samil Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Samil Pharmaceutical Co Ltd
KRX:000520
|
Operating Income
-₩16.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-25%
|
|
|
Yuhan Corp
KRX:000100
|
Operating Income
₩104.4B
|
CAGR 3-Years
43%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Operating Income
₩203.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Operating Income
₩257.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
39%
|
CAGR 10-Years
2%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Operating Income
₩8.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-9%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Operating Income
₩20.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Samil Pharmaceutical Co Ltd
Glance View
SAMIL PHARMACEUTICAL Co., Ltd. engages in the development and manufacture of pharmaceutical products. The company is headquartered in Seoul, Seoul. The Company’s products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The firm distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.
See Also
What is Samil Pharmaceutical Co Ltd's Operating Income?
Operating Income
-16.5B
KRW
Based on the financial report for Sep 30, 2025, Samil Pharmaceutical Co Ltd's Operating Income amounts to -16.5B KRW.
What is Samil Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-25%
